GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (STU:038) » Definitions » 5-Year EBITDA Growth Rate

NovoCure (STU:038) 5-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is NovoCure 5-Year EBITDA Growth Rate?

NovoCure's EBITDA per Share for the three months ended in Mar. 2024 was €-0.33.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of NovoCure was 57.60% per year. The lowest was -13.30% per year. And the median was 10.60% per year.


Competitive Comparison of NovoCure's 5-Year EBITDA Growth Rate

For the Medical Devices subindustry, NovoCure's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where NovoCure's 5-Year EBITDA Growth Rate falls into.



NovoCure 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


NovoCure  (STU:038) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


NovoCure 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of NovoCure's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure (STU:038) Business Description

Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure (STU:038) Headlines

No Headlines